AXSM
Axsome Therapeutics, Inc.
AXSM has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over AXSM overall, supported by stronger fundamentals and stronger modeled upside.
AXSM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Unavailable |
AXSM's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
AXSM PE Valuation
AXSM has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 83x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
AXSM Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect AXSM to return to profit, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
AXSM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.74 | — |
| Q3 2026 | -$3.05 | +$1.62 |
| Q2 2026 | -$3.74 | +$1.33 |
| Q1 2026 | -$3.72 | +$2.05 |
| Q4 2025 | -$3.68 | +$2.31 |
| Q3 2025 | -$4.67 | +$1.93 |
| Q2 2025 | -$5.07 | +$1.51 |
| Q1 2025 | -$5.77 | +$0.68 |
| Q4 2024 | -$5.99 | -$0.72 |
AXSM is still losing money, but far less than before: $3.05 per share over the past year, against $6.60 at its worst in late 2024.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over AXSM on earnings quality, reporting a profit while its opponent remains loss making.
AXSM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $259.7M | +52% |
| Q2 2026 | $218.4M | +46% |
| Q1 2026 | $191.2M | +57% |
| Q4 2025 | $196M | +65% |
| Q3 2025 | $171M | +63% |
| Q2 2025 | $150M | +72% |
| Q1 2025 | $121.5M | +62% |
| Q4 2024 | $118.8M | +66% |
AXSM has the edge over OSCR on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -4.3% | +23 points |
| Q2 2026 | -23% | +1.7 points |
| Q1 2026 | -33% | +14 points |
| Q4 2025 | -14% | +47 points |
| Q3 2025 | -27% | +33 points |
| Q2 2025 | -24% | +65 points |
| Q1 2025 | -47% | +43 points |
| Q4 2024 | -61% | +76 points |
AXSM's operating margin was −4.3% last quarter, up 23 points from the same quarter a year ago, near the top of its range since 2022.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR's revenue has grown year over year every quarter since early 2021: $5.1B last quarter, up 72% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over AXSM on profitability, with a higher operating margin.
AXSM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$9.7M | -1078% |
| Q2 2026 | -$33.4M | -$966K |
| Q1 2026 | -$20.8M | +$22.9M |
| Q4 2025 | -$18.7M | +$7.5M |
| Q3 2025 | $988K | +$19.7M |
| Q2 2025 | -$32.4M | -$2.3M |
| Q1 2025 | -$43.7M | +$9.9M |
| Q4 2024 | -$26.2M | +$4.1M |
AXSM has burned cash in almost every quarter: −$83M over the past year, against −$101M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over AXSM on cash generation, producing positive trailing cash flow while its opponent burns cash.
AXSM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.2% | +645K shares |
| 1 year | +4.8% | +2.4M shares |
| 3 years | +11% | +5.3M shares |
| 5 years | +39% | +14.8M shares |
| Available history | +54% | +18.4M shares |
AXSM has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
AXSM Net Leverage
AXSM's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
AXSM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 33.6 | Neutral |
| Stochastic | 13.4 | Oversold |
AXSM's weekly RSI is 34 (neutral) and its Stochastic is 13 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
AXSM PE vs Healthcare Sector
AXSM has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
AXSM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $158.3 | 8.8% below |
| 20 week MA | $195.1 | 26% below |
| 50 week MA | $191.3 | 25% below |
| 100 week MA | $152.4 | 5.3% below |
| 200 week MA | $114.9 | 26% above |
AXSM has fallen below most of its moving averages, though it's still 26% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over AXSM on trend strength, trading above more of its moving averages.
AXSM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $102.0 | $84.9 | -17% |
| 2021 | $84.9 | $38.5 | -55% |
| 2022 | $38.5 | $73.8 | +92% |
| 2023 | $73.8 | $79.6 | +7.9% |
| 2024 | $79.6 | $86.7 | +8.9% |
| 2025 | $86.7 | $152.1 | +75% |
| 2026 YTD | $152.1 | $144.4 | -5.1% |
AXSM has finished higher in four of the last six years, two of them by more than 50%. It's down 5.1% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over AXSM on returns for 2026, with the stronger performance.